SectorBiological Technology
Established Date--
Listing Date09/02/2024
ExchangeNASDAQ Stock Exchange
Full-time Employees119
Fiscal Year Ends31/12
Security TypeCommon stock
Office address5959 Horton Street, 7th Floor, Emeryville, California 94608
Business
IntroductionMetagenomi Therapeutics, Inc., was originally formed in September 2016 and started its existing business as a Delaware limited liability company in 2018. The company is an in vivo gene editing company focused on the development of curative gene medicines using proprietary gene editing tools derived from metagenomics. Its wholly-owned lead project, MGX-001, aims to treat hemophilia A and continues to advance its R&D pipeline for genetic diseases through a variety of editing methods.
